HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rituximab in central nervous system manifestations of patients with primary Sjögren's syndrome: results from the AIR registry.

AbstractOBJECTIVES:
To evaluate the efficacy of rituximab in central nervous system (CNS) manifestations of patients with primary Sjögren's syndrome (pSS).
METHODS:
Prospective data from patients with pSS and CNS involvement included in the French AutoImmunity and Rituximab registry were analysed. All patients had diffuse white matter T2-weigted hypersignals. Neurological response was defined as improvement or disappearance of neurological signs.
RESULTS:
Eleven patients (mean age 55 years [38-77]) were treated with rituximab for their neurological involvement. The mean duration of pSS was 9 years (4-24). Mean baseline ESSDAI score was 17 (5-25). Neurological features were progressive multiple sclerosis-like manifestations (n=6), transverse myelitis (n=1), anxiety and depression disorder (n=1) and cognitive dysfunction (n=3). Mean Expanded Disability Status Score (EDSS) before rituximab was 4 (3-5.5). The mean follow-up was of 13 months (6-58). No neurological change occurred in all 6 patients with multiple sclerosis-like symptoms, in 2/3 patients with cognitive dysfunction or in the patient with anxiety-depression. One patient with depression and cognitive dysfunction disclosed subjective improvement. One patient with transverse myelitis, refractory to cyclophosphamide had an improvement of his walk perimeter (160 meters vs. 116). Mean EDSS score and ESSDAI remained stable.
CONCLUSIONS:
Rituximab does not seem to be effective in progressive multiple sclerosis-like manifestations of patients with pSS-related CNS involvement.
AuthorsArsene Mekinian, Philippe Ravaud, Claire Larroche, Eric Hachulla, Bruno Gombert, Claire Blanchard-Delaunay, Alain Cantagrel, Olivier Fain, Jean Sibilia, Jacques-Eric Gottenberg, Xavier Mariette, Club Rhumatismes et Inflammation
JournalClinical and experimental rheumatology (Clin Exp Rheumatol) 2012 Mar-Apr Vol. 30 Issue 2 Pg. 208-12 ISSN: 0392-856X [Print] Italy
PMID22341206 (Publication Type: Journal Article, Multicenter Study)
Chemical References
  • Antibodies, Monoclonal, Murine-Derived
  • Antirheumatic Agents
  • Rituximab
Topics
  • Adult
  • Aged
  • Antibodies, Monoclonal, Murine-Derived (adverse effects, therapeutic use)
  • Antirheumatic Agents (adverse effects, therapeutic use)
  • Central Nervous System Diseases (diagnosis, drug therapy, etiology)
  • Disability Evaluation
  • Female
  • France
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Prospective Studies
  • Registries
  • Rituximab
  • Sjogren's Syndrome (complications, diagnosis, drug therapy)
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: